Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF -1-
May 14, 2001
- Hitachi to Develop New Clinical Data Management System with AstraZeneca
May 14, 2001
- REGULATORY NEWS IN BRIEF -2-
May 14, 2001
- FTC Inspects Tohoku Wholesalers on Suspicion of Price Cartel
May 14, 2001
- Kenporen Predicts 6.6% Increase in Medical Costs for Elderly
May 14, 2001
- JPMA to Prepare for ICH6 in Japan in 2003
May 14, 2001
- 10 Kinds of Advanced Medical Treatment Services Approved
May 14, 2001
- JPMA to Hold Int'l Panel Focusing on Patient-Oriented Healthcare
May 14, 2001
- Evidence on Acute Myocardial Infarctions in Japan Compiled by Korosho Study Group
May 14, 2001
- Wholesalers' FTC to Stop Members Supporting Medical Institution Social Gatherings
May 14, 2001
- Diagnostic, Treatment GL for Urinary Incontinence in Women Prepared
May 14, 2001
- BUSINESS NEWS IN BRIEF -2-
May 14, 2001
- Health Insurance Coverage for Viagra Demanded by the Public: Pfizer Seminar
May 14, 2001
- Kyowa Hakko Kogyo Aims at \300 Bil. Drug Sales in 2011: President Hirata
May 14, 2001
- 2hPG Recommended for Predicting Cardiovascular Disease Mortality: Takeda Seminar
May 14, 2001
- NBI to Increase Its Sales to \110 Bil. in 2004: President Kawabata
May 14, 2001
- GLs on Proper Use of Antibacterials Completed
May 14, 2001
- Eisai Ties Up with Neurogenetics
May 14, 2001
- OTC NEWS IN BRIEF
May 14, 2001
- BUSINESS NEWS IN BRIEF -1-
May 14, 2001
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…